Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY (Details)

v3.24.1
STOCKHOLDERS' EQUITY (Details) - Common Stock Warrants [Member]
 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Shares outstanding, Beginning 67,060
Weighted average exercise price outstanding, Beginning | $ / shares $ 524.97
Shares, Granted 6,399,061 [1]
Weighted average exercise price, Granted | $ / shares $ 4.71 [1]
Shares, Cancelled 0
Shares, Exchanged (40,260)
Weighted average exercise price, Exchanged | $ / shares $ 641.25
Shares, Expired 0
Shares, Exercised (813,774)
Weighted average exercise price, Exercised | $ / shares $ 19.38
Shares outstanding, Ending 5,612,087
Weighted average exercise price outstanding, Ending | $ / shares $ 7.04
Weighted average remaining life in years, Outstanding 4 years 10 months 13 days
Intrinsic value, Outstanding | $ $ 0
Shares, Exercisable 5,612,087
Weighted average exercise price, Exercisable | $ / shares $ 7.04
Weighted average remaining life in years, Exercisable 4 years 10 months 13 days
Intrinsic value, Exercisable | $ $ 0
[1] The number of warrants granted and the weighted average exercise price is based on the adjustment to certain warrants as of February 2, 2024, the date of the Company’s 1 for 45 reverse stock split. As discussed above, further adjustments occurred based on the change in the change in the VWAP of the Company’s common stock from February 2, 2024 and due to the exchange of the May 2023 Notes for Series A convertible preferred stock on March 4, 2024.